5 months AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal Zacks
AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.
AbbVie (ABBV) · Biotech · New York · Pharmaceuticals · Science · U.S. · York